Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab with EPOCH-R for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas
NCT07097363Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Dec 2025
- Primary completion
- May 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in B-cell non-Hodgkin lymphoma, sponsored by University of Washington. Started Dec 2025; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07097363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07097363.